摘要
老年晚期非小细胞肺癌（NSCLC）的治疗目前尚无统一标准，但一般状况较好的老年患者，单纯放疗或化疗已逐渐成为治疗的主要措施。同步放化疗综合治疗也能使部分老年患者获益，值得进一步临床研究。靶向治疗疗效确切，不良反应小，为老年晚期NSCLC治疗提供了新的治疗模式，但费用贵，一般家庭不能接受，故靶向药物及靶向药物与传统抗肿瘤治疗模式的结合尚不能广泛开展。
At present, there is no unified standards of treatment in elderly advanced non-small cell lung cancer （NSCLC） , but to elderly patients with higher KPS scores, radiotherapy or chemotherapy alone has gradually become the main treatment measures. The concurrent chemoradiotherapy can benefit to part of the eld- erly patients, and it is worth further clinical research. Targeted therapy has exactly effect, and the adverse effect is mild, which provides a new treatment model fur e, lderly advanced NSCLC patients. However, the hos- pital ensts are relatively high, which can not he accepted by ordinal＇y family. So targeted drugs and the model of combination treatment can not be applied extensively.
出处
《国际肿瘤学杂志》
CAS
2013年第1期54-57,共4页
Journal of International Oncology
基金
陕西省自然科学基金（2012JM4008）.
关键词
癌
非小细胞肺
老年人
Carcinoma, non-small-cell lung
Aged
